Roche, a Swiss drug manufacturer, announced a acquisition agreement of the US company Carmot Therapeutics.
Il cost of the operation is 2,7 billion of dollars in cash. Carmot shareholders could also receive additional payments of up to 400 million of dollars based on the achievement of specific milestones.
Carmot's entire portfolio acquired
Upon closing of the deal, Roche will acquire Carmot's entire research and development portfolio, including all clinical and preclinical resources. Carmot and its employees will join Roche as part of the company's Pharmaceutical Division.
Innovation in the treatment of obesity
Carmot Therapeutics is known for its research and development portfolio, which includes clinical-stage subcutaneous and oral incretins. These treatments show promising potential in the obesity treatment, both in diabetic and non-diabetic patients. Additionally, the company has several preclinical programs underway.
"L 'Obesity is a heterogeneous disease, which contributes to many other diseases that together constitute a significant health burden worldwide,” he said Thomas SchineckerCEO Roche – By combining Carmot's portfolio with our pharmaceutical product pipeline programs, our diagnostic expertise and product portfolio for cardiovascular and metabolic diseases, we aim to improve the standard of care and have a positive impact on patients' lives” .
